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Introduction
Familial Mediterranean fever (FMF) is an autoinflamma-
tory disorder characterized by recurrent, inflammatory,
self-limited episodes of fever and serositis. Neutrophils
are one of the key players in the pathophysiology of
FMF. Macrophage migration inhibitory factor (MIF) is a
pleiotropic cytokine involved in several inflammatory
processes including innate and adaptive immune
responses . In addition, MIF has been shown to regulate
trafficking of inflammatory cells includingneutrophis to
the sites of inflammation. Because its association with
innate immunity, leukocyte trafficking, and inflamma-
tion MIF may be considered as an attractive cytokine in
the pathogenesis of FMF.
Objectives
In this study we aimed to investigate MIF levels and its
relationship with M694V mutations in patients with
FMF.
Methods
Fifty one unrelated attack free FMF patients (14 M and
27 F, 32.8±8.7 years) and 30 healthy controls (16 M and
14 F, 32.7±7 years) were included in the study. Serum
MIF were studied and allele frequency of M694V was
calculated.
Results
Age, sex distribution, waist circumference, body mass
index, smoking status and serum lipids were not differ-
ent between the patient and control groups (P > 0.05).
On the other hand, the levels of CRP, ESR, and MIF
were significantly higher in FMF patients compared to
those of controls (P < 0.05; 4.7±7.1 vs. 1.8±2 mg/L, 15.8
±17 vs. 8.3± 5.2 mm/h, and 30.1±18.8 vs. 9±4.4 ng/mL
respectively). Comparison of patients with and without
M694V mutation revealed that MIF levels were not dif-
ferent between the groups. Regression analysis showed
that none of the variables including disease duration,
CRP, ESR, and BMI were predicting MIF concentrations
(P > 0.05).
Conclusion
In this study we showed that: (1) MIF concentrations
were significantly higher in attack-free FMF patients
compared to healthy subjects; (2) increased MIF levels
were independent from the inflammatory activity as
assessed by ESR and CRP and (3) M694V mutations
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